EXG102 and EXG202 are investigational gene therapy candidates for wet age-related macular degeneration that are in ...
Bausch + Lomb today announced the acquisition of the ELIOS system, a laser-based technology that offers a new approach to ...
ViaLase, John A. Moran Eye Center unveil research partnership to spark glaucoma research, innovation
According to the partners, glaucoma research to be led by internationally renowned glaucoma surgeon Ike Ahmed, MD, FRCSC, ...
In an interview with Ophthalmology Times, Alon Kahana, MD, PhD, discusses interleukin-6 and its role in autoimmune diseases, particularly thyroid eye disease, noting that a promising alternative under ...
Ophthalmology Times - ophthalmology news, articles, and events in a timely and accurate manner for members of the ophthalmic ...
Nona Biosciences has partnered with Kodiak Sciences to develop multi-target antibodies for ophthalmic diseases. Utilizing ...
Researchers described the presence of multiple bilateral serous retinal detachments (SRDs) found in 3 women after they used ...
The authors searched PubMed, Scopus, MEDLINE, ScienceDirect, and ClinicalTrials.gov, and selected studies based on reports ...
According to researchers, GPT-4o demonstrates potential in generating comprehensive differential glaucoma diagnoses but falls ...
EyePoint Pharmaceuticals has dosed the first patient in the LUCIA Phase 3 trial of Duravyu for wet AMD. The study evaluates ...
The company begins Phase 1 trials of oral GAL-101, targeting amyloid beta aggregation. Promising safety and efficacy in ...
SOL-1 is a superiority study being conducted under a Special Protocol Agreement (SPA) with the US Food and Drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback